

FASTNIB-5 TABLETS

Tofacitinib Citrate I.P. 8.08 mg (Eq. to
Tofacitinib 5 mg)

"Targeted JAK Inhibition for Autoimmune & Inflammatory
Disorders"

Marketed by: Human Orthocare
A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com



Product Overview

Composition (per tablet):

- Tofacitinib Citrate I.P. 8.08 mg
- Equivalent to Tofacitinib 5 mg

Oral JAK Inhibitor

Janus Kinase inhibition for targeted therapy

Immune Modulation


Reduces inflammation through pathway control

Multiple Conditions

Approved for various autoimmune disorders

Oral Convenience

Alternative to biologics with oral dosing





Mechanism of Action



JAK1 & JAK3 Inhibition

Tofacitinib selectively blocks Janus Kinase enzymes, preventing STAT pathway activation



Cytokine Suppression

Reduces signalling of IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, and interferons



Immune Regulation

Suppresses immune overactivation and inflammatory responses



Clinical Result

Reduced joint damage, inflammation, and autoimmune activity with improved patient outcomes

Indications

Fastnib-5 Tablets are recommended for the following conditions:




Rheumatoid Arthritis

Moderate to severe RA in adults who have had an inadequate response to conventional therapy



Psoriatic Arthritis

Active psoriatic arthritis in adult patients with inadequate response to previous therapy



Ankylosing Spondylitis

Active ankylosing spondylitis in adults with inadequate response to conventional therapy



Ulcerative Colitis


Moderate to severe ulcerative colitis in adults with inadequate response to conventional therapy








Other Conditions

Off-label autoimmune and inflammatory conditions as per specialist guidance

Clinical Advantages



Key Benefits of Fastnib-5:

-  **Oral Convenience**
Small-molecule alternative to biologics with no injection required
-  **Rapid Action**
Faster onset of action compared to conventional DMARDs
-  **Broad Efficacy**
Effective in patients unresponsive to methotrexate or TNF inhibitors
-  **Functional Improvement**
Enhances joint mobility, reduces pain, and improves physical function
-  **Patient Compliance**
Better adherence with convenient oral dosing regimen

Comparison with Conventional Therapies

Parameter	Fastnib-5 (Tofacitinib)	Methotrexate	Biologics (TNF Inhibitors)
Route of Administration	✓ Oral Tablet	✓ Oral/Injection	✗ Injection/IV
Onset of Action	✓ Fast (weeks)	⚠ Slow (months)	✓ Moderate
Efficacy in RA/AS/UC	✓ High	⚠ Variable	✓ High
Monitoring Needs	⚠ Regular (CBC, LFT)	⚠ Yes	✓ Yes

❗ Fastnib-5 offers the convenience of oral administration with rapid onset and high efficacy across multiple autoimmune conditions.

Dosage & Administration



Rheumatoid/Psoriatic Arthritis & Ankylosing Spondylitis

5 mg twice daily

Standard maintenance dose for optimal efficacy



Ulcerative Colitis

Induction: 10 mg twice daily

Maintenance: 5-10 mg twice daily



Specialist Guidance

Dosing as per physician or specialist advice based on individual patient needs



Important Considerations

- Adjust dose in hepatic or renal impairment
- Regular monitoring of CBC, LFTs, and lipid profile required



Safety & Tolerability

Common Side Effects

- Headache and diarrhoea
- Hypertension
- Elevated liver enzymes
- Lipid abnormalities

Serious but Rare Risks

- Opportunistic infections (TB, herpes zoster)
- Thrombosis risk at higher doses
- Malignancy risk (long-term use)

Contraindications

- Severe hepatic impairment
- Active serious infections
- Pregnancy and lactation (avoid use)

⊗ Regular monitoring and patient education are essential for safe and effective use of Fastnib-5.



Why Prescribe Fastnib-5?

Doctor's Choice For:



Targeted Therapy

Oral targeted JAK inhibitor offering convenient and effective treatment option



Strong Efficacy

Proven effectiveness in RA, PsA, AS, and UC with consistent clinical outcomes



Rapid Improvement

Quick improvement in pain, stiffness, and functional capacity for better quality of life



Alternative Option

Suitable for patients intolerant or resistant to biologics and conventional DMARDs



Trusted Quality

Reliable pharmaceutical quality from Human Orthocare with consistent manufacturing standards



Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:

 www.humanorthocare.com